Tarsus Closes $450M Alkeus Acquisition, Adds Phase 3 Stargardt Asset
TARS sits 68% above its 52-week low of $48.2.
Summary
Tarsus closed its acquisition of Alkeus Pharmaceuticals, adding the Phase 3 Stargardt disease candidate gildeuretinol (ALK-001) to its pipeline. The deal involved $270 million in cash, 2.9 million shares of stock, and up to $350 million in milestone payments.
Key Events · M&A and Partnerships · TARS
-
Alkeus Acquisition Completed
The acquisition of Alkeus Pharmaceuticals closed on September 4, 2026, with Tarsus paying $270 million in cash and issuing 2,908,692 shares of common stock valued at $180 million.
-
Phase 3 Stargardt Asset Added
The deal adds gildeuretinol (ALK-001), a Phase 3 oral therapy for Stargardt disease with Breakthrough Therapy, Orphan Drug, Fast Track, and Rare Pediatric Disease designations. Topline data from the NORTHSTAR trial is anticipated in 2029.
-
Contingent Consideration Structure
Up to $350 million in milestone payments: $250 million upon U.S. regulatory approval (payable in cash and/or stock) and $100 million upon first commercial sale in the U.S., plus tiered royalties in the low-to-mid single digits on future worldwide gildeuretinol sales.
-
Registration Rights Effective
The registration rights agreement and joinder/lock-up agreements with Alkeus equityholders became effective upon closing, providing resale registration rights for the newly issued shares.
Analysis · TARS · Life Sciences
The acquisition of Alkeus Pharmaceuticals closed on September 4, 2026, with Tarsus paying $270 million in cash and issuing 2,908,692 shares of common stock, valued at $180 million based on the $61.38 per-share reference price in the merger agreement. This brings gildeuretinol (ALK-001), a Phase 3 oral therapy for Stargardt disease with no FDA-approved treatment, into Tarsus's eye care pipeline. The filing also quantifies the contingent consideration: up to $350 million in milestone payments tied to U.S. regulatory approval and first commercial sale, plus tiered royalties on future worldwide sales. For a company with a $3.56 billion market cap, this is a significant strategic expansion, adding a potential blockbuster asset in a large inherited retinal disease market.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.6% of the 1805 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TARS was trading at $81.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $48.20 to $91.53. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.